

Review of over 15 years post-marketing safety surveillance spontaneous data for the human rotavirus vaccine (*Rotarix*) on intussusception

Journal: Drug Safety

Authorship: Tina Singh¹, Frédérique Delannois¹, François Haguinet¹, Lifeter Yenwo Molo¹

Affiliations:





¹GSK, Avenue Fleming 20, 1300 Wavre, Belgium

Corresponding author:

Tina Singh

tina.x.singh@gsk.com

Electronic supplementary material 8 Significance area for the equality test of observed and expected incidences within (a) 30 days (day 0–day 29) and (b) 7 days (day 0–day 6) after the first dose, and within (c) 30 days (day 0–day 29) and (d) 7 days (day 0–day 6) after any dose according to the reported fraction of events, worldwide



— BCL1 — BCL3
— BCL4 — Expected - - - 95%CI

— BCL1 — BCL3
— BCL4 — Expected - - - 95%CI

BCL1, Brighton Collaboration Working Group level 1; BCL3, Brighton Collaboration Working Group levels 1–3; BCL4, Brighton Collaboration Working Group levels 1–4; Low Ref. – High Ref., range of expected cases according to background incidence rates (high ref is out of scale on all panels); 95% CI, 95 percent confidence interval. Total number of doses was 319,695,721 for panels a and b (after first dose) and 639,391,442 for panels c and d (after any dose).